Immunic of Germany Set For Nasdaq After Merger With Failed Vital Therapies
The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.
You may also be interested in...
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
The UK company, which postponed plans for a US offering in April, has taken the M&A route to secure a Nasdaq listing by combining with OncoMed.